<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052687</url>
  </required_header>
  <id_info>
    <org_study_id>CLFX453X2101</org_study_id>
    <secondary_id>2013-002344-84</secondary_id>
    <nct_id>NCT02052687</nct_id>
  </id_info>
  <brief_title>A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453</brief_title>
  <official_title>A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453, After Multiple Topical Applications in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in human study is to demonstrate systemic and local tolerability
      and investigate pharmacokinetics of LFX453 after multiple topical applications in healthy
      subjects.

      The current study has been designed with three distinct parts. Part 1 focuses on safety and
      tolerability of once daily application on the back, prior to moving forward and assessing the
      safety and tolerability in more sensitive treatment areas in Part 2 or twice daily
      application in Part 3.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General safety (number of subjects with adverse events)</measure>
    <time_frame>14 days</time_frame>
    <description>Summarized statistics on adverse events will be reported under categories such as total adverse events, serious adverse events and death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local skin tolerability (tolerability score)</measure>
    <time_frame>14 days</time_frame>
    <description>Summarized statistics on 5-point scale tolerability scores over 14 days of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All parts: Amount (ng/mL) of LFX453 in plasma</measure>
    <time_frame>14 days</time_frame>
    <description>Evaluate systemic steady state pharmacokinetics in human after topical administration of LFX453.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: LFX453 concentrations (ng/g) in the skin</measure>
    <time_frame>Day 14 and between days 18-21</time_frame>
    <description>LFX453 analyzed in skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All parts: LFX453 concentration (ng/mL) in urine</measure>
    <time_frame>Day 14</time_frame>
    <description>LFX453 analyzed in urine.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: LFX453/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 groupA: LFX453/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily: LFX453 cream 1 / Placebo 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 groupB: LFX453/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily: LFX453 cream 2 / Placebo 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 groupC: LFX453/LFX453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily: LFX453 cream 1 / LFX453 cream 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 groupD: Imiquimod</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>once daily: imiquimod cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: LFX453/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFX453 H1</intervention_name>
    <description>LFX453 high dose cream 1</description>
    <arm_group_label>Part 1: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupA: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupB: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupC: LFX453/LFX453</arm_group_label>
    <arm_group_label>Part 3: LFX453/placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFX453 L1</intervention_name>
    <description>LFX453 low dose cream 1</description>
    <arm_group_label>Part 1: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupA: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupB: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupC: LFX453/LFX453</arm_group_label>
    <arm_group_label>Part 3: LFX453/placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFX453 H2</intervention_name>
    <description>LFX453 high dose cream 2</description>
    <arm_group_label>Part 1: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupA: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupB: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupC: LFX453/LFX453</arm_group_label>
    <arm_group_label>Part 3: LFX453/placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFX453 L2</intervention_name>
    <description>LFX453 low dose cream 2</description>
    <arm_group_label>Part 1: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupA: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupB: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupC: LFX453/LFX453</arm_group_label>
    <arm_group_label>Part 3: LFX453/placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>Imiquimod cream</description>
    <arm_group_label>Part 2 groupD: Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1</intervention_name>
    <description>Placebo cream 1</description>
    <arm_group_label>Part 1: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupA: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupB: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 3: LFX453/placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 2</intervention_name>
    <description>Placebo cream 2</description>
    <arm_group_label>Part 1: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupA: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 2 groupB: LFX453/placebo</arm_group_label>
    <arm_group_label>Part 3: LFX453/placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects of non-childbearing potential, 18 to 65 years of age
             inclusive (at the time of the screening visit), and in good health as determined by
             past medical history, physical examination, vital signs, electrocardiogram, and
             laboratory tests at screening.

          -  Male subjects must agree to total abstinence from male:female intercourse or agree to
             use a condom during drug dosing and for four weeks after dosing has stopped.

        Exclusion Criteria:

          -  History of serious allergic reaction to any drug.

          -  History of hypersensitivity to any of the study drugs or to drugs of similar chemical
             classes.

          -  History of any atopic dermatitis (only within the last 2 years), autoimmune disease,
             psoriasis or erythema multiforme.

          -  Presence of skin disease (e.g. warts) or skin features on treatment areas that may
             affect local tolerability or the ability of the investigator to evaluate local
             tolerability.

          -  History of heart failure, left ventricular dysfunction or known family history or
             known presence of long QT syndrome.

          -  A history of clinically significant ECG abnormalities, or any of the following ECG
             abnormalities at screening or baseline:

               -  2nd or 3rd degree AV-block

               -  PR &gt; 200 msec

               -  QRS complex &gt; 120 msec

               -  QTcF &gt; 450 msec (males)

               -  QTcF &gt; 460 msec (females)

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test.

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mid Glamorgan</city>
        <zip>CF484DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>May 14, 2015</last_update_submitted>
  <last_update_submitted_qc>May 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

